Synapse Biomedical

Focus: Synapse Biomedical is a publicly traded biotechnology company focused on neuromuscular and respiratory therapeutics, centered on its NeuRx Diaphragm Pacing System platform. The company addresses unmet needs in neurology and respiratory conditions through implantable neuromodulation devices.

Neurology Respiratory Unknown

Profile data last refreshed 9h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Synapse Biomedical

AI assessmentNot Hiring

No open roles listed right now. Follow Synapse Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NeuRx Diaphragm Pacing System

Diaphragm Issues

N/A

Clinical Trials (1)

NCT04457427Randomized Study to Investigate the Safety and Performance of Diaphragm Stimulation Coupled With Mechanical Ventilation

N/A

Help build intelligence for Synapse Biomedical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused portfolio in high-unmet-need areas (ALS, spinal cord injury, ventilator-induced dysfunction) with clinical relevance to multiple therapeutic areas.
Public company status provides stability and potential equity upside not available at early-stage ventures.
Specialized neuromodulation platform (NeuRx DPS) represents a differentiated technology approach with multiple indication pathways under investigation.

Watch Out For

Zero active job openings signals potential organizational contraction or hiring freeze despite public status.
Pipeline remains primarily in Phase 2 or preclinical phases with no Phase 3 programs evident, limiting near-term clinical catalysts and regulatory visibility.
Limited financial transparency (no revenue, R&D spend, or cash position data available) creates uncertainty about runway and organizational health.

Generated by Claude from Synapse Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

TransLoc electrode

Diaphragm Pacing

N/A

Clinical Trials (1)

NCT02410798Clinical Study to Investigate Safety and Performance of TransLoc Electrodes in Patients Undergoing Surgical Procedures

N/A

TransAeris System

Ventilator-Induced Diaphragm Dysfunction

N/A

Clinical Trials (1)

NCT05404477Study of TransAeris® System for Enhanced Recovery After Surgery in France

N/A